ClinicalTrials.gg
RecruitingNCT05864404Updated May 30, 2023

Comparison of Patients' Satisfaction Between Dexmedetomidine and Remimazolam Anesthesia in Patients With Atrial Fibrillation Undergoing Catheter Ablation

An interventional study of remimazolam-remifentanil and dexmedetomidine-remifentanil in Patients With Atrial Fibrillation Undergoing Catheter Ablation, sponsored by Yonsei University. Recruiting at 1 site in Korea, Republic of. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2023-05-30.

Sponsored by Yonsei University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
20 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Atrial Fibrillation by Yonsei University — 25 open to participants now, 26 under way, none of them phase 3. Atrial Fibrillation · Yonsei University.

Planned enrollment
27th of 42
142 · median 259
Started
2023
with 1 other
No phase
35 of 52
19 open now
Primary completion
2024-10
later than 0 of 25 live
Registered
37th of 52
by date

Among the 52 studies in Atrial Fibrillation by Yonsei University, this one is the 27th largest by planned enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2023, is one of 35 with no phase, reaches primary completion later than 0 of the 25 other live ones, and was the 37th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

25 of the 52 studies in Atrial Fibrillation by Yonsei University are open now, in 1 country. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 20 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Atrial Fibrillation by Yonsei University, or all of them as a file.
02

Study summary

The primary purpose of this study was to investigate whether remimazolam administration for sedation had a positive effect on patients' satisfaction compared to dexmedetomidine administration in patients with atrial fibrillation undergoing catheter ablation.

Atrial fibrillation is a common arrhythmia in clinical practice. Catheter ablation can be used when the cause of atrial fibrillation is in the pulmonary veins. However, the procedure takes 2 to 4 hours, and patients complain of considerable discomfort. Remimazolam has the advantage of having no drug interaction with CYP3A4 and shorter elimination half-life, duration of action, and shorter recovery time than midazolam, a previously used drug. In addition, compared to dexmedetomidine, side effects such as bradycardia and hypotension are expected to be less. In addition, even if unexpected deep sedation is induced, complete reversal using flumazenil is possible, so the risk of re-sedation could be low.

In other words, when remimazolam is used instead of a drug previously used as a sedative in atrial fibrillation patients undergoing catheter ablation, effects such as rapid action and recovery, reduced complications, improved safety, and improved patient satisfaction can be expected. Therefore, this study was designed to confirm the hypothesis that administration of remimazolam would improve satisfaction in patients undergoing catheter ablation compared to dexmedetomidine.

03

Conditions studied

  • Patients With Atrial Fibrillation Undergoing Catheter Ablation

Browse trials for

04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 20-79 years, gender not limited
  • Patients undergoing catheter ablation for atrial fibrillation who require monitored anesthetic care (MAC).
  • Patients with an (ASA) physical status classification 1,2,3.

Exclusion criteria

Exclusion Criteria:

  • Patients with an (ASA) physical status classification >3.
  • Patients with a history of psychiatric disorders
  • Patients with myocardial infarction or stroke within the past year
  • Patients with a history of major vascular surgery or cardiac surgery within the past year
  • Patients with reduced liver function, chronic kidney disease (stage 3 or higher)
  • Patients diagnosed with heart failure with a \<40%
  • Patients who need vasopressor or oxygen therapy due to unstable vital signs before procedure.
  • Patients with fever (>38°) or severe uncontrolled high blood pressure
  • Patients with a history of drug during previous anesthesia
  • Patients who are unable to communicate and have cognitive impairment
  • Patients with a history of drug or alcohol addiction
  • Patients with a history of obstructive sleep apnea
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
142 participants (estimated)

Study arms

  • Experimental
    remimazolam-remifentanil (RR group)

    Drug: remimazolam-remifentanil

  • Active comparator
    dexmedetomidine-remifentanil (DR group)

    Drug: dexmedetomidine-remifentanil

Interventions

  • Drugremimazolam-remifentanil

    In the case of remimazolam, the bolus is prepared in a 30cc syringe by mixing 0.075mg/kg and normal saline to make a total of 25mL. Inject the bolus at a rate of 150 cc/h, and measure the sedation depth every 2 to 3 minutes, stopping the infusion when the target sedation depth (RASS -1 to -2 points) is reached. Remimazolam is then infused at 0.5 to 1 mg/kg/hr to maintain the target depth of sedation until the end of the procedure. Remifentanil was infused at a rate of 1.2-7.2 mcg/kg/h.

  • Drugdexmedetomidine-remifentanil

    In the case of dexmedetomidine, the bolus is prepared in a 30cc syringe by mixing 1.0mcg/kg and normal saline to make a total of 25mL. Inject the bolus at a rate of 150 cc/h, and measure the sedation depth every 2 to 3 minutes, stopping the infusion when the target sedation depth (RASS -1 to -2 points) is reached. Dexmedetomidine is then infused at 0.4 to 0.8 mcg/kg/h to maintain the target depth of sedation until the end of the procedure. Remifentanil was infused at a rate of 1.2-7.2 mcg/kg/h.

06

What researchers measure

Primary outcomes

  1. The satisfaction levels of the patients

    The satisfaction levels of the patients was assessed with a 5-point numerical scale (0=extremely dissatisfied, 1=dissatisfied, 2=neutral, 3=satisfied, and 4=extremely satisfied).

    Time frame: Immediately after the procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Oct 2024, 16 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 16 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2023
First posted
May 18, 2023
StartActual
May 24, 2023
Primary completionEst.
Oct 9, 2024
CompletionEst.
Oct 9, 2024
Last update
May 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05864404
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
May 18, 2023
Start date
May 24, 2023
Primary completion
Oct 9, 2024 (estimated)
Completion
Oct 9, 2024 (estimated)
Last update
May 30, 2023

Study contacts

Sarah Soh
Contact
yeonchoo@yuhs.ac
82-2-2228-8512

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion